Armstrong Wants Extra Year To Develop Inhaler Without Epinephrine
This article was originally published in The Tan Sheet
Executive Summary
Generic manufacturer Armstrong Pharmaceuticals is asking FDA to delay for a year until 2011 the agency's proposed rule that would force epinephrine-containing metered-dose inhalers off the market
You may also be interested in...
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market
Armstrong’s Primatene Mist Inhaler Has 2011 Deadline To Exit The Market
Generics manufacturer Armstrong Pharmaceuticals now has until the end of 2011 to remove Primatene Mist and private-label epinephrine inhalers from the market